Companies / Consumer Staples
ADM
Archer Daniels Midland
Agricultural Products & Services
Agricultural Products & ServicesAnalysis in progress
In progress
We are decoding this company's strategy and relationships
New analyses are published every weekday. Founding members get them first.
Business at a glance
Operating-health scores describe reported fundamentals on a 0–100 scale. They are not a rating of the stock. How they work
Operating health58
Growth24
Profitability25
Cash generation84
Balance sheet68
Dilution control91
Key ratios and five-year financials
Latest quarter revenue YoY (2026-09-30)3.3%Revenue growth (FY)2.4%Revenue CAGR (3y)-3.3%Gross margin20.2%Operating margin—Net margin4.3%Free cash flow margin16.8%R&D / revenue1.0%Stock comp / revenue0.3%Net debt / operating cash flow1.54xCurrent ratio1.37Diluted share count change-1.8%
| Fiscal year ending | FY 2021-12 | FY 2022-12 | FY 2023-12 | FY 2024-12 | FY 2025-12 |
|---|---|---|---|---|---|
| Revenue | $85.2B | $27.6B | $25.7B | $24.4B | $25.0B |
| Gross profit | $6.0B | $7.6B | $7.5B | $5.8B | $5.0B |
| Net income | $2.7B | $4.3B | $3.5B | $1.8B | $1.1B |
| Operating cash flow | $6.6B | $3.5B | $4.5B | $2.8B | $5.5B |
| Capital expenditure | $1.2B | $1.3B | $1.5B | $1.6B | $1.2B |
| Free cash flow | $5.4B | $2.2B | $3.0B | $1.2B | $4.2B |
| R&D | $171M | $216M | $256M | $269M | $246M |
| Stock-based comp | $161M | $147M | $112M | $74M | $83M |
| Buybacks | $0 | $1.4B | $2.7B | $2.3B | $0 |
| Dividends | $834M | $899M | $977M | $985M | $987M |
| Cash | $943M | $1.0B | $1.4B | $611M | $1.0B |
| Total debt | $10.1B | $10.1B | $8.4B | $10.8B | $9.4B |
| Equity | $22.5B | $24.3B | $24.1B | $22.2B | $22.7B |
StratGraph publishes general, impersonal research about public companies based on public filings. It is not investment advice, not a recommendation to buy, sell or hold any security, and not tailored to any reader's circumstances. Content may contain errors and may be partly generated with AI tools; verify against the original filings, which are linked. Authors may not trade securities discussed within the window set by our trading policy. Full disclaimer.